Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 6/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253207 | 0.86 | TSHR (0.44) | CES2TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL22247042 | 0.86 | CES2 (0.51) | CES2TSHRSMN1; SMN2GLP1RRECQL | |
| SCHEMBL1669396 | 0.85 | CES2 (0.40) | CES2TSHRMEN1KMT2ARECQL | |
| SCHEMBL21440820 | 0.85 | GLP1R (0.40) | CES2TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL18239530 | 0.84 | TSHR (0.38) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL23729785 | 0.83 | SMN1; SMN2 (0.50) | CES2TSHRSMN1; SMN2GLP1RALDH1A1 | |
| SCHEMBL23729610 | 0.83 | CES2 (0.49) | CES2TSHRSMN1; SMN2GLP1RRECQL | |
| SCHEMBL24483723 | 0.83 | MEN1 (0.39) | CES2TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18551609 | 0.81 | CES2 (0.52) | CES2TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL21242622 | 0.81 | CES2 (0.42) | CES2TSHRSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | CES2 1255/4885TSHR 3198/4885SMN1; SMN2 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.